Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | AB INBEV | 3 | 30 | -0,69 % | |
| UCB | 3 | - | -0,58 % | |
| ELIA GROUP | 1 | 4 | +0,29 % | |
| GBL | 1 | 1 | -0,31 % | |
| ARGENX | - | 10 | -0,31 % | ||
| MELEXIS | - | 4 | +3,00 % | |
| UMICORE | - | 2 | -0,11 % | |
| AGEAS | - | 1 | +0,73 % | |
| KBC GROEP NV | - | 1 | +0,38 % | |
| MONTEA | - | 1 | -1,65 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:38 | ANHEUSER-BUSCH INBEV SA/NV: Ruhe vor der nächsten Bewegung | 3 | Maximilian Berger | ||
| 06:38 | Why BlackRock's investment in Anheuser-Busch InBev didn't shake the market | 15 | IOL | ||
| Mo | GBL: GBL - Transactions on GBL shares 20-04-2026 | 1 | Euronext | ||
| Mo | Interview with Laurein Cornelissen, Team Lead Expertise Power Transformers at Elia | 3 | Transformers | ||
| Mo | BERNSTEIN RESEARCH stuft AB Inbev auf 'Outperform' | 538 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für AB Inbev von 83 auf 87 Euro angehoben und die Einstufung auf "Outperform" belassen. Trevor Stirling zog in einer... ► Artikel lesen | |
| Mo | UCB Proposes $650M Acquisition of Neurona Therapeutics | 5 | Contract Pharma | ||
| Mo | UCB to purchase Neurona and NRTX-1001 for $1.15bn | 1 | Pharmaceutical Technology | ||
| Mo | UCB cuts $1.15bn deal to buy epilepsy biotech Neurona | 4 | pharmaphorum | ||
| Mo | ARGENX SE - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Italy's private equity weekly roundup. News from BeBeez, Di Luccia & Partners, Banca Investis, Duke&Kay, Recordati, CVC, Groupe Bruxelles Lambert, Adia, Gic, Caisse de Depot et Placement du Quebec, and more | 5 | BeBeez | ||
| Mo | KBC Groep: Notification for bondholders of KBC IFIMA | 237 | GlobeNewswire (Europe) | Following document is available on www.kbc.com:
- 2025 financial report of KBC IFIMA
► Artikel lesen | |
| Mo | ANHEUSER-BUSCH INBEV SA/NV - Disclosure Made According to the Requirements of the Law of 2 May 2007 | 4 | SENS | ||
| Sa | Should Altria sell off its Anheuser-Bush InBev stake? It's complicated | 42 | Seeking Alpha | ||
| Sa | argenx SE: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | 4 | GlobeNewswire (USA) | ||
| Fr | UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B | 2 | BioPharma Dive | ||
| Fr | Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B | 4 | Seeking Alpha | ||
| Fr | UCB übernimmt Neurona Therapeutics für bis zu 1,15 Milliarden US-Dollar | 2 | Investing.com Deutsch | ||
| Fr | UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine | 11 | FierceBiotech | ||
| Fr | UCB to acquire Neurona Therapeutics for up to $1.15 billion | 2 | Investing.com | ||
| Fr | UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | 968 | PR Newswire | Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.
... ► Artikel lesen |
1 2 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.